MEREO BIOPHARMA GROUP PL-ADR (MREO) Forecast, Price Target & Analyst Ratings
NASDAQ:MREO • US5894921072
0.3876 USD
-0.01 (-1.65%)
Last: Mar 9, 2026, 12:19 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MEREO BIOPHARMA GROUP PL-ADR (MREO).
Forecast Snapshot
Consensus Price Target
$1.79
+ 360.53% Upside
Next Earnings Forecast
Release DateMar 23, 2026
PeriodQ4 / 2025
EPS Estimate-$0.01
Revenue Estimate
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.79
Upside
+ 360.53%
From current price of $0.39 to mean target of $1.79, Based on 14 analyst forecasts
Low
$0.51
Median
$1.53
High
$3.15
Price Target Revisions
1 Month
0.00%
3 Months
-75.00%
Price Target Summary
14 analysts have analysed MREO and the average price target is 1.79 USD. This implies a price increase of 360.53% is expected in the next year compared to the current price of 0.3876.
The average price target has been revised downward by 75% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
MREO was analyzed by 14 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MREO.
In the previous month the buy percentage consensus was at a similar level.
MREO was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-16 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-13 | Needham | Maintains | Buy -> Buy |
| 2025-12-30 | Jefferies | Downgrade | Buy -> Hold |
| 2025-12-29 | LifeSci Capital | Downgrade | Outperform -> Market Perform |
| 2025-12-29 | BTIG | Maintains | Buy -> Buy |
| 2025-12-22 | Needham | Reiterate | Buy -> Buy |
| 2025-12-18 | BTIG | Reiterate | Buy -> Buy |
| 2025-08-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-10 | Needham | Maintains | Buy -> Buy |
| 2025-05-13 | Needham | Reiterate | Buy -> Buy |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-03-27 | JP Morgan | Initiate | Overweight |
| 2025-03-26 | Needham | Reiterate | Buy -> Buy |
| 2025-03-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2024-12-24 | LifeSci Capital | Initiate | Outperform |
| 2024-12-06 | Jefferies | Initiate | Buy |
| 2024-11-12 | Needham | Reiterate | Buy -> Buy |
| 2024-10-01 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-13 | Needham | Reiterate | Buy -> Buy |
| 2024-07-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-06-13 | Baird | Initiate | Outperform |
| 2024-06-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 23, 2026
PeriodQ4 / 2025
EPS Estimate-$0.01
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q73.76%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
-100.00%
EPS (1 Month)
0.00%
EPS (3 Months)
-221.50%
Next Earnings Summary
MREO is expected to report earnings on 3/23/2026. The consensus EPS estimate for the next earnings is -0.01 USD and the consensus revenue estimate is 0 USD.
The next earnings revenue estimate has been revised downward by 100% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 50.14M | -100.00% | 10M | -100.00% | 530.4K | 34.28M 6,363.05% | 47.528M 38.65% | 159.56M 235.72% | 44.477M -72.13% | 105.2M 136.53% | 173.12M 64.56% | 245.35M 41.72% | 347.71M 41.72% | |
| EBITDA YoY % growth | -27.905M 39.49% | -52.781M -89.15% | -27.355M 48.17% | -53.026M -69.17% | -73.233M -58.25% | -26.145M 64.30% | 9.856M 137.70% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.788M 40.24% | -53.677M -86.46% | -28.416M 47.06% | -43.817M -66.68% | -49.161M -3.79% | -28.301M 42.43% | -27.287M 3.58% | 46.196M 269.30% | -44.462M -196.25% | 1.803M 104.06% | 58.979M 3,171.16% | 119.53M 102.67% | 211.43M 76.88% | |
| Operating Margin | -57.42% | N/A | -284.16% | N/A | -9,268.61% | -82.56% | -57.41% | 28.95% | -99.97% | 1.71% | 34.07% | 48.72% | 60.81% | |
| EPS YoY % growth | N/A 91.18% | N/A -47.54% | N/A 38.67% | -0.06 -8.58% | -0.06 -3.75% | -0.03 44.45% | -0.04 -20.01% | 0.05 211.50% | -0.05 -201.35% | 0.00 100.00% | 0.06 | 0.12 108.48% | 0.20 73.07% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.01 73.76% | 0.00 97.96% | -0.01 93.88% | -0.01 -22.40% | -0.01 61.12% |
| Revenue Q2Q % growth | 8.925M | 4.335M 767.00% | 40.341M | ||
| EBITDA Q2Q % growth | 39.78M 380.40% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.843M 22.47% | -1.646M 85.04% | -6.369M 39.34% | -11.028M -10.12% | 5.206M 143.96% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
9.37%
EPS Next 5 Year
4.03%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
30.55%
EBIT Next 5 Year
N/A
MEREO BIOPHARMA GROUP PL-ADR / MREO Forecast FAQ
What is the average price target for MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
14 analysts have analysed MREO and the average price target is 1.79 USD. This implies a price increase of 360.53% is expected in the next year compared to the current price of 0.3876.
Can you provide the upcoming earnings date for MEREO BIOPHARMA GROUP PL-ADR?
MEREO BIOPHARMA GROUP PL-ADR (MREO) will report earnings on 2026-03-23, after the market close.
Can you provide the consensus estimates for MEREO BIOPHARMA GROUP PL-ADR next earnings?
The consensus EPS estimate for the next earnings of MEREO BIOPHARMA GROUP PL-ADR (MREO) is -0.01 USD and the consensus revenue estimate is 0 USD.
How do analysts rate MEREO BIOPHARMA GROUP PL-ADR (MREO)?
The consensus rating for MEREO BIOPHARMA GROUP PL-ADR (MREO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.